impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Full Papers

 

Romosozumab effect on neutrophil-to-lymphocyte ratio in post-menopausal women at high risk of fracture

1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

 

  1. Rheumatology Unit, University of Verona, Italy; and Rheumatology Department, Unidade Local de Saúde de São João, Porto, Portugal.
  2. Rheumatology Unit, University of Verona, Italy.
  3. Rheumatology Unit, University of Verona, Italy.
  4. Rheumatology Unit, University of Verona, Italy.
  5. Rheumatology Unit, University of Verona, Italy.
  6. Rheumatology Unit, University of Verona, Italy.
  7. Rheumatology Unit, University of Verona, Italy.
  8. Rheumatology Unit, University of Verona, Italy.
  9. Rheumatology Unit, University of Verona, Italy.
  10. Rheumatology Unit, University of Verona, Italy.
  11. Rheumatology Unit, University of Verona, Italy.
  12. Rheumatology Unit, University of Verona, Italy. giovanni.adami@univr.it

CER19324
Full Papers

purchase article

PMID: 41779600 [PubMed]

Received: 18/09/2025
Accepted : 12/12/2025
In Press: 04/03/2026

Abstract

OBJECTIVES:
Romosozumab (ROMO) is a monoclonal antibody targeting sclerostin (SOST), a key regulator of bone metabolism. It has been demonstrated that changes in SOST levels can affect distinct niches within the bone marrow that support haematopoiesis. This study investigated the effect of ROMO on complete blood count (CBC) parameters.
METHODS:
We conducted a 12-month prospective observational study in post-menopausal women with severe osteoporosis treated with ROMO 210 mg/monthly over one year between October 2023 and April 2025. CBC values were assessed at baseline, 6 and 12 months. Absolute changes in CBC were assessed with a mixed model for repeated measures.
RESULTS:
A total of 113 women (mean age of 73.4±9.7 years) were included. Neutrophils levels slightly decreased over time, with a significant decrease at 6 months (p=0.022), that was not sustained at 12 months (p=0.500). Haemoglobin and lymphocytes levels showed no significant differences over the period of the study. In the overall trend across time points, there was a statistically significant decrease in the neutrophil-to-lymphocyte ratio (NLR) over the 12 months (2.0 ± 1.1 at baseline, 1.8 ± 1.1 at month 6, and 1.8 ± 1.2 at month 12; p=0.034), with a small effect size (Cohen’s δ = 0.22).
CONCLUSIONS:
In post-menopausal women with severe osteoporosis, 12 months of ROMO treatment was associated with a statistically significant reduction in NLR, reflecting a potential modulation of systemic inflammation, though the clinical relevance of this modest shift remains uncertain and warrants further investigation.

DOI: https://doi.org/10.55563/clinexprheumatol/toszpl

Rheumatology Article